26° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition
STOCKING STUFFER CONTEST

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.49 -0.14 (-0.25%)

Streaming Delayed Price Updated: 3:57 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights

November 20, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

November 20, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Halper Sadeh LLC Encourages JAMF, CADE, AKRO, GES Shareholders to Contact the Firm to Discuss Their Rights

November 07, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

From Halper Sadeh LLC

Via GlobeNewswire

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

November 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD)

November 06, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Halper Sadeh LLC Encourages AL, FFWM, AKRO, HNI Shareholders to Contact the Firm to Discuss Their Rights

October 30, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

October 29, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Halper Sadeh LLC Investigates AKRO, CCRD, PBBK on Behalf of Shareholders

October 22, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)

October 22, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders

October 16, 2025

From Halper Sadeh LLC

Via GlobeNewswire

October 16, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk ↗

October 15, 2025

Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases.

Via Investor's Business Daily

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

October 10, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

October 10, 2025

Via Benzinga

Wall Street Pulls Back as Earnings Season Kicks Off; PepsiCo, Delta, and Costco Defy the Trend ↗

October 10, 2025

U.S. markets took a step back on Thursday, with the Dow and Nasdaq closing lower. Still, some heavyweights bucked the trend: PepsiCo, Delta Air Lines, and Costco all reported stronger-than-expected...

Via Chartmill

Topics Stocks

Why Akero Therapeutics Stock Trounced the Market on Thursday ↗

October 09, 2025

The biotech will soon have a new owner.

Via The Motley Fool

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗

October 09, 2025

Via Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates AKRO, CCRD, AL, PBBK on Behalf of Shareholders

October 09, 2025

From Halper Sadeh LLC

Via GlobeNewswire

October 09, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday ↗

October 09, 2025

Via Benzinga

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion ↗

October 09, 2025

Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.

Via Benzinga

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout ↗

October 09, 2025

The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 09, 2025

Via Benzinga

AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders

October 09, 2025

From Halper Sadeh LLC

Via Business Wire

Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch ↗

October 09, 2025

Via Stocktwits

Topics Economy Stocks

What’s Driving The Super Rally In Akero Shares On Thursday Morning? ↗

October 09, 2025

Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right.

Via Stocktwits

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

October 09, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

October 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO

September 18, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

All News about Akero Therapeutics, Inc. - Common Stock

Sections

Services